

## Update on ePAT for Infant Apps

### Highlights:

- ePAT plans to develop three Apps for children covering the age groups of 0-1 years, 1-3 years and older than 3 years.
- Apps use a combination of automated facial recognition technology and common pain behaviours in infants.
- Development is expected to commence in October this year with a prototype available for initial validation testing in March 2017.
- ePAT has engaged with experts in facial micro-expression, nVISO, to develop prototypes of the App.
- Apps are targeted to be available for sale by July 2018.
- Significant opportunities both nationally and internationally.

MinQuest Limited (ASX: MNQ) (“MinQuest” or “the Company”) is pleased to provide an update on Australian-based medical research company Electronic Pain Assessment Technology (ePAT) Pty Ltd’s (“ePAT”) revolutionary pain assessment Apps for infants.

ePAT for infants is a novel pain assessment tool that combines automated facial recognition technology and common pain expressions with the aim of guiding clinicians, carers and parents to identify pain in pre-verbal children including newborns, infants and toddlers.

ePAT chief executive officer Professor Jeff Hughes said other means of detecting pain would also be used for younger children, particularly infants, who were too difficult to console and which would make facial recognition impossible.

“The Apps are planned to incorporate automated analysis of the child’s cry as another means of detecting the presence of pain,” Professor Hughes said.

“As with the App for non-communicative adults, other features associated with pain, including movement, behaviour and the ability to comfort the child, will be collected through the Apps to allow for calculation of a pain severity score.”

Professor Hughes said there were major opportunities both nationally and internationally for the infant Apps.

“Pain is an inevitable experience to everyone including pre-verbal children. Following birth, children get exposed to a variety of things which are associated with pain, such as injuries, illnesses and immunisations,” Professor Hughes said.

“These Apps will assist clinicians, carers and parents to more effectively identify pain in children, which can be very challenging.”

01 June 2016

### DIRECTORS

Frank Terranova  
*Non- Executive Chairman*

Jeremy Read  
*Managing Director*

Paul Niardone  
*Non-Executive Director*

Adam Davey  
*Non-Executive Director*

Stephen Kelly  
*Company Secretary*

### SHARE INFORMATION

ASX Code: MNQ  
Issued Capital:  
296,805,545 Fully Paid  
Shares  
72,936,522 Listed Options  
15,619,853 Unlisted Options

### CONTACT INFORMATION

Registered Office:  
Unit 1, 47 Park Road  
Milton, QLD 4064  
T: +61 7 3511 6570  
F: +61 7 3369 3305  
[www.minquest.com.au](http://www.minquest.com.au)

### MEDIA ENQUIRIES

Colin Jacoby  
Professional Public  
Relations Pty Ltd  
T: +61 8 9388 0944  
M: + 61 411 828 073

MinQuest Limited  
ACN: 146 035 127

ePAT plans to develop a series of Apps for infants to address changes in facial structure in the early years of life.

The Apps make similar use of facial recognition technology to the ePAT App for dementia sufferers (refer to ASX announcements dated 19 May and 25 May 2016), however the range of facial micro-expressions which indicate the presence of pain will be expanded in line with available evidence from the literature.

To facilitate development of the Apps, ePAT has commenced compilation of a library of audio-visual recordings of infants and young children with and without pain.

BabyFACS<sup>1</sup> coding has been completed on a sample of twenty infant videos which will be used in the development of ePAT's infant App.

Development of the Apps is expected to commence in October this year with prototypes available for initial validation testing in the first half of 2017. ePAT has engaged with experts in facial micro-expression, nVISO, to develop prototypes of the Apps.

All three Apps are targeted to be available for sale by July 2018.

It is proposed that the ePAT for infants Apps may be commercialised as follows:

- Business-to-Consumer (B2C): Available to millions of parents or carers of young preverbal children via the Apple App store and Google Play store.
- Business-to-Business (B2B): Under licence through patient care software vendors to medical practices, outpatient clinics and hospitals.

### **About ePAT**

On 14 April 2016, MinQuest announced that it has entered in a binding heads of agreement to acquire 100% of the issued capital of ePAT. ePAT is developing revolutionary mobile medical applications that use facial recognition software to facilitate and improve pain assessment in patients that are unable to communicate.

The App is being developed and rolled out in two phases; one for patients with dementia who have lost the ability to communicate with their carers and the second for infants who have not yet learnt to speak. The ePAT Apps are being developed for the global market, initially for health care professionals and professional carers of patients with dementia and subsequently for parents and carers of infants.

## **Forward Looking Statements**

This announcement contains "forward-looking statements". Such forward-looking statements include, without limitation: proposed developments in the Company's business; estimates of future earnings, the sensitivity of earnings to commodity prices and foreign exchange rate movements; estimates of future production and sales; estimates of future cash flows, the sensitivity of cash flows to commodity prices and foreign exchange rate movements; statements regarding future debt repayments; estimates of future capital expenditures; estimates of resources and statements regarding future exploration results; and where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, forward looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Such risks include, but are not limited to competition with the Company's business activities, changes in technology, the ability of the Company to obtain and maintain any required regulatory approvals for its current or proposed business activities, commodity price volatility, currency fluctuations, increased production costs and variances in resource or reserve rates from those assumed in the company's plans, as well as political and operational risks in the countries and states in which we operate or sell product to, and governmental regulation and judicial outcomes. For a more detailed discussion of such risks and other factors, see the Company's Annual Reports, as well as the Company's other filings. The Company does not undertake any obligation to release publicly any revisions to any "forward looking statement" to reflect events or circumstances after the date of this release, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities law.